Literature DB >> 18565900

Measurement of residual disease after neoadjuvant chemotherapy.

Catherine Abrial, Emilie Thivat, Olivier Tacca, Xavier Durando, Marie-Ange Mouret-Reynier, Pierre Gimbergues, Frédérique Penault-Llorca, Philippe Chollet.   

Abstract

Mesh：

Year:  2008        PMID： 18565900     DOI： 10.1200/JCO.2008.16.7817

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  4 in total

1.  Reproducibility of residual cancer burden for prognostic assessment of breast cancer after neoadjuvant chemotherapy.

Authors:  Florentia Peintinger; Bruno Sinn; Christos Hatzis; Constance Albarracin; Erinn Downs-Kelly; Jerzy Morkowski; Rebekah Gould; W Fraser Symmans
Journal:  Mod Pathol       Date:  2015-05-01       Impact factor: 7.842

2.  Identification of biomarkers of response to preoperative talazoparib monotherapy in treatment naïve gBRCA+ breast cancers.

Authors:  Xuan Liu; Zhongqi Ge; Fei Yang; Alejandro Contreras; Sanghoon Lee; Jason B White; Yiling Lu; Marilyne Labrie; Banu K Arun; Stacy L Moulder; Gordon B Mills; Helen Piwnica-Worms; Jennifer K Litton; Jeffrey T Chang
Journal:  NPJ Breast Cancer       Date:  2022-05-10

3.  Automatic cellularity assessment from post-treated breast surgical specimens.

Authors:  Mohammad Peikari; Sherine Salama; Sharon Nofech-Mozes; Anne L Martel
Journal:  Cytometry A       Date:  2017-10-04       Impact factor: 4.355

Review 4.  Evaluation of the Efficacy of Neoadjuvant Chemotherapy for Breast Cancer.

Authors:  Huan Wang; Xiaoyun Mao
Journal:  Drug Des Devel Ther       Date:  2020-06-18       Impact factor: 4.162
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.